Nucleic Acid Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB506240726

Publication Date:

June 10, 2024

Pages:

113

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

Nucleic Acid Drugs are pharmaceutical compounds that target nucleic acids (DNA or RNA) for therapeutic purposes, including gene therapy and antisense therapy.
The global market for Nucleic Acid Drugs was estimated to be worth US$ 76 million in 2023 and is forecast to a readjusted size of US$ 267.6 million by 2030 with a CAGR of 18.4% during the forecast period 2024-2030
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Nucleic Acid Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Nucleic Acid Drugs by region & country, by Type, and by Application.
The Nucleic Acid Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Nucleic Acid Drugs.
Market Segmentation
By Company
Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Mina Therapeutics
BioNTech
NeXstar Pharmaceuticals
Nippon Shinyaku
Moderna Therapeutics
CureVac
Regulus Therapeutics
Miragen Therapeutics
Segment by Type:
Antisense Nucleic Acid Drugs
siRNA Drugs
saRNA Drugs
miRNA Drugs
mRNA Drugs
other
Segment by Application
Genetic Disease
Cancer
Cardiovascular Diseases
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Nucleic Acid Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Nucleic Acid Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Nucleic Acid Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Nucleic Acid Drugs Product Introduction
1.2 Global Nucleic Acid Drugs Market Size Forecast
1.3 Nucleic Acid Drugs Market Trends & Drivers
1.3.1 Nucleic Acid Drugs Industry Trends
1.3.2 Nucleic Acid Drugs Market Drivers & Opportunity
1.3.3 Nucleic Acid Drugs Market Challenges
1.3.4 Nucleic Acid Drugs Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Nucleic Acid Drugs Players Revenue Ranking (2023)
2.2 Global Nucleic Acid Drugs Revenue by Company (2019-2024)
2.3 Key Companies Nucleic Acid Drugs Manufacturing Base Distribution and Headquarters
2.4 Key Companies Nucleic Acid Drugs Product Offered
2.5 Key Companies Time to Begin Mass Production of Nucleic Acid Drugs
2.6 Nucleic Acid Drugs Market Competitive Analysis
2.6.1 Nucleic Acid Drugs Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Nucleic Acid Drugs Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Nucleic Acid Drugs as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Antisense Nucleic Acid Drugs
3.1.2 siRNA Drugs
3.1.3 saRNA Drugs
3.1.4 miRNA Drugs
3.1.5 mRNA Drugs
3.1.6 other
3.2 Global Nucleic Acid Drugs Sales Value by Type
3.2.1 Global Nucleic Acid Drugs Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Nucleic Acid Drugs Sales Value, by Type (2019-2030)
3.2.3 Global Nucleic Acid Drugs Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Genetic Disease
4.1.2 Cancer
4.1.3 Cardiovascular Diseases
4.1.4 Other
4.2 Global Nucleic Acid Drugs Sales Value by Application
4.2.1 Global Nucleic Acid Drugs Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Nucleic Acid Drugs Sales Value, by Application (2019-2030)
4.2.3 Global Nucleic Acid Drugs Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Nucleic Acid Drugs Sales Value by Region
5.1.1 Global Nucleic Acid Drugs Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Nucleic Acid Drugs Sales Value by Region (2019-2024)
5.1.3 Global Nucleic Acid Drugs Sales Value by Region (2025-2030)
5.1.4 Global Nucleic Acid Drugs Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Nucleic Acid Drugs Sales Value, 2019-2030
5.2.2 North America Nucleic Acid Drugs Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Nucleic Acid Drugs Sales Value, 2019-2030
5.3.2 Europe Nucleic Acid Drugs Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Nucleic Acid Drugs Sales Value, 2019-2030
5.4.2 Asia Pacific Nucleic Acid Drugs Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Nucleic Acid Drugs Sales Value, 2019-2030
5.5.2 South America Nucleic Acid Drugs Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Nucleic Acid Drugs Sales Value, 2019-2030
5.6.2 Middle East & Africa Nucleic Acid Drugs Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Nucleic Acid Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Nucleic Acid Drugs Sales Value
6.3 United States
6.3.1 United States Nucleic Acid Drugs Sales Value, 2019-2030
6.3.2 United States Nucleic Acid Drugs Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Nucleic Acid Drugs Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Nucleic Acid Drugs Sales Value, 2019-2030
6.4.2 Europe Nucleic Acid Drugs Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Nucleic Acid Drugs Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Nucleic Acid Drugs Sales Value, 2019-2030
6.5.2 China Nucleic Acid Drugs Sales Value by Type (%), 2023 VS 2030
6.5.3 China Nucleic Acid Drugs Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Nucleic Acid Drugs Sales Value, 2019-2030
6.6.2 Japan Nucleic Acid Drugs Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Nucleic Acid Drugs Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Nucleic Acid Drugs Sales Value, 2019-2030
6.7.2 South Korea Nucleic Acid Drugs Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Nucleic Acid Drugs Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Nucleic Acid Drugs Sales Value, 2019-2030
6.8.2 Southeast Asia Nucleic Acid Drugs Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Nucleic Acid Drugs Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Nucleic Acid Drugs Sales Value, 2019-2030
6.9.2 India Nucleic Acid Drugs Sales Value by Type (%), 2023 VS 2030
6.9.3 India Nucleic Acid Drugs Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Sarepta Therapeutics
7.1.1 Sarepta Therapeutics Profile
7.1.2 Sarepta Therapeutics Main Business
7.1.3 Sarepta Therapeutics Nucleic Acid Drugs Products, Services and Solutions
7.1.4 Sarepta Therapeutics Nucleic Acid Drugs Revenue (US$ Million) & (2019-2024)
7.1.5 Sarepta Therapeutics Recent Developments
7.2 Ionis Pharmaceuticals
7.2.1 Ionis Pharmaceuticals Profile
7.2.2 Ionis Pharmaceuticals Main Business
7.2.3 Ionis Pharmaceuticals Nucleic Acid Drugs Products, Services and Solutions
7.2.4 Ionis Pharmaceuticals Nucleic Acid Drugs Revenue (US$ Million) & (2019-2024)
7.2.5 Ionis Pharmaceuticals Recent Developments
7.3 Alnylam
7.3.1 Alnylam Profile
7.3.2 Alnylam Main Business
7.3.3 Alnylam Nucleic Acid Drugs Products, Services and Solutions
7.3.4 Alnylam Nucleic Acid Drugs Revenue (US$ Million) & (2019-2024)
7.3.5 Mina Therapeutics Recent Developments
7.4 Mina Therapeutics
7.4.1 Mina Therapeutics Profile
7.4.2 Mina Therapeutics Main Business
7.4.3 Mina Therapeutics Nucleic Acid Drugs Products, Services and Solutions
7.4.4 Mina Therapeutics Nucleic Acid Drugs Revenue (US$ Million) & (2019-2024)
7.4.5 Mina Therapeutics Recent Developments
7.5 BioNTech
7.5.1 BioNTech Profile
7.5.2 BioNTech Main Business
7.5.3 BioNTech Nucleic Acid Drugs Products, Services and Solutions
7.5.4 BioNTech Nucleic Acid Drugs Revenue (US$ Million) & (2019-2024)
7.5.5 BioNTech Recent Developments
7.6 NeXstar Pharmaceuticals
7.6.1 NeXstar Pharmaceuticals Profile
7.6.2 NeXstar Pharmaceuticals Main Business
7.6.3 NeXstar Pharmaceuticals Nucleic Acid Drugs Products, Services and Solutions
7.6.4 NeXstar Pharmaceuticals Nucleic Acid Drugs Revenue (US$ Million) & (2019-2024)
7.6.5 NeXstar Pharmaceuticals Recent Developments
7.7 Nippon Shinyaku
7.7.1 Nippon Shinyaku Profile
7.7.2 Nippon Shinyaku Main Business
7.7.3 Nippon Shinyaku Nucleic Acid Drugs Products, Services and Solutions
7.7.4 Nippon Shinyaku Nucleic Acid Drugs Revenue (US$ Million) & (2019-2024)
7.7.5 Nippon Shinyaku Recent Developments
7.8 Moderna Therapeutics
7.8.1 Moderna Therapeutics Profile
7.8.2 Moderna Therapeutics Main Business
7.8.3 Moderna Therapeutics Nucleic Acid Drugs Products, Services and Solutions
7.8.4 Moderna Therapeutics Nucleic Acid Drugs Revenue (US$ Million) & (2019-2024)
7.8.5 Moderna Therapeutics Recent Developments
7.9 CureVac
7.9.1 CureVac Profile
7.9.2 CureVac Main Business
7.9.3 CureVac Nucleic Acid Drugs Products, Services and Solutions
7.9.4 CureVac Nucleic Acid Drugs Revenue (US$ Million) & (2019-2024)
7.9.5 CureVac Recent Developments
7.10 Regulus Therapeutics
7.10.1 Regulus Therapeutics Profile
7.10.2 Regulus Therapeutics Main Business
7.10.3 Regulus Therapeutics Nucleic Acid Drugs Products, Services and Solutions
7.10.4 Regulus Therapeutics Nucleic Acid Drugs Revenue (US$ Million) & (2019-2024)
7.10.5 Regulus Therapeutics Recent Developments
7.11 Miragen Therapeutics
7.11.1 Miragen Therapeutics Profile
7.11.2 Miragen Therapeutics Main Business
7.11.3 Miragen Therapeutics Nucleic Acid Drugs Products, Services and Solutions
7.11.4 Miragen Therapeutics Nucleic Acid Drugs Revenue (US$ Million) & (2019-2024)
7.11.5 Miragen Therapeutics Recent Developments
8 Industry Chain Analysis
8.1 Nucleic Acid Drugs Industrial Chain
8.2 Nucleic Acid Drugs Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Nucleic Acid Drugs Sales Model
8.5.2 Sales Channel
8.5.3 Nucleic Acid Drugs Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Sarepta Therapeutics
Ionis Pharmaceuticals
Alnylam
Mina Therapeutics
BioNTech
NeXstar Pharmaceuticals
Nippon Shinyaku
Moderna Therapeutics
CureVac
Regulus Therapeutics
Miragen Therapeutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂